[Leukocyte migration inhibition and leukocyte adherence inhibition (LMI- and LAI-assay) in cancer patients by using preparations from human fetuses].
The sensitization of lymphocytes from patients with different tumors was tested against a 3 M KCl-extract of fetal tissue (3.--6. month) by the leukocyte adherence inhibition assay (LAI) and by the leukocyte migration inhibition assay (LMI). Sensitization was compared with the reactivity of controls without any detectable tumor. In the LAI assay the leukocytes of 13/15 patients and 2/12 controls showed an inhibition of the adherence. In the LMI-assay 11/17 tumor-bearing patients and 6/18 controls reacted positive in the presence of the antigen preparation. The two methods demonstrated that patients bearing tumors of different histology are sensitized to fetal antigens.
D000818:Animals; D000941:Antigens; D002464:Cell Migration Inhibition; D005260:Female; D005333:Fetus; D006801:Humans; D007158:Immunologic Techniques; D007957:Leukocyte Adherence Inhibition Test; D007962:Leukocytes / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D011247:Pregnancy
D000941:Antigens
Leukozytenmigrationsinhibitions-(LMI-)-und Leukozyten-adhärenzinhibitions-(LAI-)-Test bei Patienten mit Tumoren unter Verwendung von Fetalantigenpräparation.